Amit Munshi

About Amit Munshi

Amit was most recently Chief Executive Officer & President of ReNAgade Therapeutics, acquired by Orna Therapeutics. Previously as President and CEO of Arena Pharmaceuticals Inc.(Nasdaq:ARNA), he led the $300m market cap company through a turnaround process including revamping the Board of Directors and management, resetting priorities, and migrating the company from a retail base to an institutionally-backed company. In December 2021, Pfizer (NYSE: PFE) acquired ARNA for approximately $6.7B. At Arena, he sput out Longboard, recently acquired by Lundbeck A/S for approximately $2.6BFrom 20••••16, Amit was President & CEO of EPIRUS Biopharmaceuticals, Inc, Prior to EPIRUS, he was President and CEO of Percivia LLC, a Crucell NV and Royal DSM NV joint-venture focused on biotherapeutics on the PER.C6® cell platform. Amit was brought in to lead the turnaround and reset strategy for Percivia, which was acquired by Johnson and Johnson (NYSE:JNJ) in 2012. Before Percivia, Amit identified the lead asset (KYBELLA®), co-founded and was the Chief Business Officer of Kythera Biopharmaceuticals Inc.(Nasdaq:KYTH), a company focused on novel prescription therapeutics in aesthetic medicine. At KYTHERA Mr. Munshi led several rounds of financing and completed a $370M ex-North America license transaction with a division of Bayer. KYTH was sold to Allergan (NYSE:AGN) for $2.1B.Prior to co-founding Kythera, Amit spent 8 years at Amgen Inc. Mr. Munshi was the General Manager of Amgen’s European Nephrology Business based in Switzerland with responsibility for ARANESP® and Mimpara®/Sensipar®. Prior to Switzerland, he was responsible for Amgen’s inflammation / immunology marketing including the launch of KINERET® and playing a leading role in the acquisition of Immunex Corp (Nasdaq:IMNX), sales and marketing integration and the re-launch of Enbrel®. Previous to working at Amgen, Amit held commercial positions during tenures at Astra Merck (Prilosec®) and IOLAB Corporation (a JNJ Company). Amit is also a co-founder of Oxeia Biopharmaceuticals, Inc (Private) and a member of the board of directors of Enterprise Therapeutics (Private), and public companies - Galecto (GLTO), Inhibikase Therapeutics (IKT), Zura Bio (Zura) and Sensorion SA (ALSEN). He is also an advisor to Bank Pictet and Ares Capital.Amit received a MBA from The Peter Drucker Graduate School of Management at Claremont Graduate University and holds a BA in History and a BS in Quantitative Economics from the University of California, Riverside.

Experience

1. Chairman

   Sensorion

   Apr 2025 — Present

Education

• University of California, Riverside

  BA, BS, History, Economics

  1986 — 1990

• Drucker School of Management

  MBA

  1991 — 1993